[NMusers] RE: Generating TAD with ADDL dosing format

From: Pitsiu, Maria <Maria.Pitsiu_at_iconplc.com>
Date: Tue, 20 Dec 2016 13:14:24 +0000

Hi Camila

If you don't have a lag time, use the following:
$PK
IF(NEWIND.LT.2) THEN
IFL=0
TAD=0.0
ENDIF
IF(EVID.EQ.1.OR.EVID.EQ.4)DTIME=TIME
 IF(DOSTIM.NE.0.)DTIME=DOSTIM ; non-event dose times

TAD=TIME-DTIME

If you have a lag time, use:
IF(NEWIND.LT.2) THEN
TAD=0.0
DTIME=1.0E+06
ENDIF

IF(DOSTIM>0.0) DTIME=DOSTIM -ALAG1 ; dostim is non-zero on =
additional doses (ADDL/II), no delay in doses
IF(AMT>0.AND.DOSTIM==0.0) DTIME=TIME ; for all dose events s=
cheduled explcitly in the data record, no delay
TAD=TIME-DTIME

I hope this helps

Maria


Maria Pitsiu ICON Plc PK M&S 7122 3652 (internal) +44 162 849 3652 (externa=
l)

From: owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com] On=
 Behalf Of de Almeida, Camila
Sent: 20 December 2016 13:46
To: nmusers_at_globomaxnm.com
Subject: [NMusers] Generating TAD with ADDL dosing format

Hello,

I was wondering if I could get some guidance from this great group. My issu=
e is primarily with some diagnostic analysis, but this is taking me back to=
 an old NONMEM problem.

My aim is to run a VPC on a model I implemented, and if possible change the=
 idv to TAD instead of TIME. The reason for that is the VPC graph based on =
TIME looks dreadful as the data is sparse and from different studies of dif=
ferent lengths.

I'm having issues generating the TAD output column from my NONMEM run. I na=
ively assumed I could easily do that, but looking at the NONMEM archives it=
 seems this gets tricky when your dosing events are written using ADDL. Has=
 anyone ever managed to find a solution for this? And if not, is there an a=
lternative way to run the VCP on TAD, do we really need to get this column =
from NONMEM's output?

Thanks all,

Camila de Almeida, PhD
PKPD Scientist,
Modelling & Simulation, IMED Oncology DMPK
___________________________________________________________________________=
_____
AstraZeneca UK Limited
R&D, Innovative Medicines

P Please consider the environment before printing this e-mail








________________________________
AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number:03674842 and its registered office at 1 Francis Crick Ave=
nue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient =
only and may contain confidential and privileged information. If they have =
come to you in error, you must not copy or show them to anyone; instead, pl=
ease reply to this e-mail, highlighting the error to the sender and then im=
mediately delete the message. For information about how AstraZeneca UK Limi=
ted and its affiliates may process information, personal data and monitor c=
ommunications, please see our privacy notice at www.astrazeneca.com<https:/=
/www.astrazeneca.com> <br /><br /> ICON plc made the following annotati=
ons. --------------------------------------------------------------------=
---------- This e-mail transmission may contain confidential or legally p=
rivileged information that is intended only for the individual or entity na=
med in the e-mail address. If you are not the intended recipient, you are=
 hereby notified that any disclosure, copying, distribution, or reliance up=
on the contents of this e-mail is strictly prohibited. If you have receiv=
ed this e-mail transmission in error, please reply to the sender, so that I=
CON plc can arrange for proper delivery, and then please delete the message=
. Thank You, ICON plc South County Business Park Leopardstown=



Received on Tue Dec 20 2016 - 08:14:24 EST

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:53:10 EDT